Research News
The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Taking a unique approach to better diagnose and treat one of the world’s leading causes of blindness, a researcher from the University of Canberra in Australia has received a $500,000 boost for his three-year project, thanks to a grant from BrightFocus Foundation’s Macular Degeneration Research program.
A new study bridging neuroscience and machine learning offers insights into the potential role of astrocytes in the human brain.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
Harnessing the power of artificial intelligence, researchers have identified nearly 200 previously unknown DNA regions linked to a risk of developing glaucoma, findings that could lead to new ways of preventing the disease.
A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
For the first time, a research team has created laboratory-grown cone photoreceptor cells that respond to light, unlocking a potential new way to treat macular degeneration.
Research awarded by BrightFocus totals nearly $290 million to date across 25 countries, enabling innovative scientists from around the world to push the boundaries of Alzheimer’s, macular degeneration, and glaucoma research.
Donanemab, a potential new amyloid-clearing Alzheimer’s drug, has been shown to slow cognitive decline by 35% in the early stages of Alzheimer’s disease.
Blacks and Hispanics with neuropsychiatric symptoms are more likely to develop cognitive impairment, according to recent BrightFocus-funded research.